Farther Finance Advisors LLC Increases Stock Holdings in Zoetis Inc. $ZTS

Key Points

• Farther Finance Advisors LLC increased its Zoetis Inc. shareholding by 151.1%, owning 11,895 shares valued at approximately $1.86 million after acquiring additional shares in the second quarter.
• Several large institutional investors also significantly bought into Zoetis, with Nuveen LLC leading with a new stake valued at $616 million during the first quarter.
• Zoetis reported an earnings per share (EPS) of $1.76 for the last quarter, exceeding expectations, with a year-over-year revenue increase of 4.2%.

Farther Finance Advisors LLC grew its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 151.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,895 shares of the company's stock after buying an additional 7,157 shares during the quarter. Farther Finance Advisors LLC's holdings in Zoetis were worth $1,855,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in ZTS. Nuveen LLC acquired a new stake in shares of Zoetis during the first quarter valued at $616,375,000. Sarasin & Partners LLP acquired a new stake in shares of Zoetis during the first quarter valued at $339,111,000. Mackenzie Financial Corp boosted its stake in shares of Zoetis by 4,158.3% during the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company's stock valued at $300,481,000 after acquiring an additional 1,782,110 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Zoetis by 14,731.3% during the first quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company's stock valued at $289,666,000 after acquiring an additional 1,747,423 shares during the last quarter. Finally, Polen Capital Management LLC boosted its stake in shares of Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock valued at $1,448,401,000 after acquiring an additional 1,313,653 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $144.73 on Tuesday. The company has a market cap of $64.14 billion, a P/E ratio of 24.91, a PEG ratio of 2.34 and a beta of 0.88. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a one year low of $139.70 and a one year high of $197.51. The business's 50-day simple moving average is $151.03 and its 200 day simple moving average is $156.27.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company's revenue was up 4.2% on a year-over-year basis. During the same period last year, the business posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of analyst reports. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and decreased their price target for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Piper Sandler raised their price target on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Finally, Argus reissued a "buy" rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Zoetis presently has an average rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.